SCHEMBL6560813

SCHEMBL6560813

CCS(=O)(=O)N(C)C1CC(C)(C)Oc2ccc(C(=O)OC)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNE1 P15382 11/20 0.42
KCNQ1 P51787 11/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
KCND3 Q9UK17 1/20 0.40
KCNA5 P22460 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 1/20 0.36
TSHR P16473 2/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
CNR2 P34972 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6559333 0.93 KCNE1 (0.44) KCNE1KCNQ1MEN1KMT2ACYP1A2
SCHEMBL6559205 0.89 SMN1; SMN2 (0.38) KCNE1KCNQ1MEN1KMT2ACYP1A2
SCHEMBL6559277 0.89 KCNE1 (0.40) KCNE1KCNQ1MEN1KMT2ASMN1; SMN2
SCHEMBL6558501 0.89 KCNE1 (0.45) KCNE1KCNQ1MEN1KMT2ACYP1A2
SCHEMBL6559569 0.88 RAB9A (0.37) MEN1KMT2AKCNA5SMN1; SMN2RAB9A
SCHEMBL6559388 0.87 KCNE1 (0.43) KCNE1KCNQ1MEN1KMT2ACYP1A2
SCHEMBL6559604 0.87 MEN1 (0.36) KCNE1KCNQ1MEN1KMT2ACYP1A2
SCHEMBL6559826 0.86 SMN1; SMN2 (0.36) MEN1KMT2AKCNA5SMN1; SMN2RAB9A
SCHEMBL6559952 0.86 KCNA5 (0.41) KCNE1KCNQ1MEN1KMT2ACYP1A2
SCHEMBL6558710 0.85 KCNA5 (0.35) KCNE1KCNQ1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0807629-B1 Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them AVENTIS PHARMA GMBH (DE) 2004-03-03 EP claimed
US-6191164-B1 POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 2001-02-20 US claimed
EP-0807629-A1 Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them HOECHST AKTIENGESELLSCHAFT (DE) 1997-11-19 EP claimed
EP-0807629-B1 Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them AVENTIS PHARMA GMBH (DE) 2004-03-03 EP disclosed
US-6191164-B1 POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 2001-02-20 US disclosed
EP-0807629-A1 Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them HOECHST AKTIENGESELLSCHAFT (DE) 1997-11-19 EP disclosed